Hexima Investor Updates

Upcoming CEO Presentations

Shareholders are invited to attend a presentation by Hexima CEO Dr Nicole van der Weerden. To view a copy of the presentation click here. Dr van der Weerden will present in Melbourne on Monday 26th June at 11am at Lvl 21, 333 Collins Street (offices of Arnold Bloch Liebler). A second presentation will be held in Sydney in the near future, with further details to be advised.

read more

Hexima Shareholder Update and Share Trading

Hexima is pleased to advise that it has completed a pivotal GLP repeat-dose dermal irritation study in minipigs for HPX124 which should provide sufficient pre-clinical animal toxicology data to support a first-in-human clinical trial for HXP124 as a treatment of onychomycosis. Further details are provided in the presentation.

read more

Archives